SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma informs about post buyback public announcement

26 Feb 2022 Evaluate

Pursuant to Regulation 24(vi) of the Buyback Regulations, Ajanta Pharma has informed that the Company issued a public advertisement dated 25th February, 2022 (the ‘Post Buyback Public Announcement’) for the Buyback of 11,20,000 Equity Shares, at a price of Rs 2,550, on a proportionate basis from the equity shareholders of the Company as on the record date 14th January 2022 through the tender offer process. The Post Buyback Public Announcement has been published on 26th February 2022 in newspapers, Business Standard (English & Hindi) in all edition and Pratahkal (Marathi) in Mumbai. The e-clippings of the said Advertisement are enclosed.

The above information is a part of company’s filings submitted to BSE.

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×